Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etelcalcetide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.43 |
| ▸ | NPY4R | P50391 | 11/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY1R | P25929 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etelcalcetide SCHEMBL22578458 | 1.00 | SIRT5 (0.43) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL28425407 | 1.00 | SIRT5 (0.43) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL20869502 | 0.99 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL21982605 | 0.99 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL20869503 | 0.99 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| Etelcalcetide SCHEMBL22578460 | 0.94 | SIRT5 (0.49) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24991307 | 0.94 | SIRT5 (0.44) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19912225 | 0.92 | NPY4R (0.40) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16690663 | 0.86 | NPY4R (0.48) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16690636 | 0.86 | NPY4R (0.48) | SIRT5NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3730134-B1 | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS | EA PHARMA CO LTD (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-11311508-B2 | Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis | EA PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200397731-A1 | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS | EA PHARMA CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3730134-A1 | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS | EA Pharma Co., Ltd. (JP) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311508-B2 | Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis | PTH1R, PTMS, REN | SIRT5 1786/4885NPY4R 4566/4885NPY5R 2769/4885 |
| US-20200397731-A1 | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS | PTH1R, PTMS, REN | SIRT5 1786/4885NPY4R 4566/4885NPY5R 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.